ArticleNew microbes and new infections2020
Consideration of dornase alfa for the treatment of severe COVID-19 acute respiratory distress syndrome.
Article in New microbes and new infections, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04402970 (Inhaled Dornase Alfa for Treatment of ARDS in Patients With SARS-CoV-2), which is not on this map. Cited by 39 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Inhaled Dornase Alfa for Treatment of ARDS in Patients With SARS-CoV-2
Who cites it
39 citing papers in PubMed, 2 syntheses or guidelines pooled it, 62 citations in OpenAlex.
- Use of dornase alfa in the paediatric intensive care unit: current literature and a national cross-sectional survey.European journal of hospital pharmacy : science and practice · 2022Pooled it
- Systematic review: cystic fibrosis in the SARS-CoV-2/COVID-19 pandemic.BMC pulmonary medicine · 2021Pooled it
- Non-Randomized Trial of Dornase Alfa for Acute Respiratory Distress Syndrome Secondary to Covid-19.Frontiers in immunology · 2021Trial
- DNase I as a probe for unpolymerized actin: revisiting a classic tool for nuclear actin research.Pflugers Archiv : European journal of physiology · 2026Review
- The Interaction of Neutrophil Extracellular Traps and Complement in Intracerebral Hemorrhage.Cellular and molecular neurobiology · 2026Review
- Training the Lung, Taming the NETs.Frontiers in cellular and infection microbiology · 2026Article
- A tissue-penetrably engineered deoxyribonuclease 1 to prevent nasal polyp formation in chronic rhinosinusitis.BMC pharmacology & toxicology · 2025Article
- Uncomplicated SARS-CoV-2 Infections with Preserved Lung Function in Pediatric Patients with Cystic Fibrosis: A Three-Year Single-Centre Experience.Journal of clinical medicine · 2025Article
- Physiology and pathophysiology of mucus and mucolytic use in critically ill patients.Critical care (London, England) · 2025Review
- Case report:Frontiers in veterinary science · 2025Article
- An Overview of SARS-CoV-2 Potential Targets, Inhibitors, and Computational Insights to Enrich the Promising Treatment Strategies.Current microbiology · 2024Review
- Neutrophil extracellular traps in CSF and serum of dogs with steroid-responsive meningitis-arteritis.PloS one · 2024Article
- Occurrence of COVID-19 in cystic fibrosis patients: a review.Frontiers in microbiology · 2024Review
- Crosslink between SARS-CoV-2 replication and cystic fibrosis hallmarks.Frontiers in microbiology · 2023Review
- Neutrophil heterogeneity and aging: implications for COVID-19 and wound healing.Frontiers in immunology · 2023Review
- Self-DNA driven inflammation in COVID-19 and after mRNA-based vaccination: lessons for non-COVID-19 pathologies.Frontiers in immunology · 2023Article
- Cytokine Storm and Neuropathological Alterations in Patients with Neurological Manifestations of COVID-19.Current Alzheimer research · 2022Article
- Detection of Extracellular Traps in Canine Steroid-Responsive Meningitis-Arteritis.Frontiers in veterinary science · 2022Article
- Neutrophils in COVID-19: Not Innocent Bystanders.Frontiers in immunology · 2022Review
- Solid Dosage Forms of Biopharmaceuticals in Drug Delivery Systems Using Sustainable Strategies.Molecules (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
We propose a likely contribution to severe COVID-19 morbidity by extracellular DNA in neutrophil extracellular traps (NETs). Dornase alfa degrades extracellular DNA to reduce mucus rigidity and accumulation, and was associated with respiratory improvement in a first patient. Dornase alfa should be considered for clinical trials in treatment of severe COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.